Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Desseigne

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimenT André, M A Bensmaine, C Louvet, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2002
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancerM Ychou, J L Raoul, F Desseigne, et al.
Clinics and Research in Hepatology and Gastroenterology|June 3, 2011
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatmentE Samalin, P Afchain, S Thézenas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2009
A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study groupI Ray-Coquard, S Dussart, C Goillot, et al.
British Journal of Cancer|January 11, 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trialE Samalin, O Bouché, S Thézenas, et al.
The British Journal of Radiology|December 6, 2002
Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteriaV Trillet-Lenoir, G Freyer, P Kaemmerlen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2019
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trialO Trédan, Q Wang, D Pissaloux, et al.
ESMO Open|January 30, 2021
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancerP Heudel, S Chabaud, D Perol, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimenT André, M A Bensmaine, C Louvet, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2002
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancerM Ychou, J L Raoul, F Desseigne, et al.
Clinics and Research in Hepatology and Gastroenterology|June 3, 2011
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatmentE Samalin, P Afchain, S Thézenas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2009
A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study groupI Ray-Coquard, S Dussart, C Goillot, et al.
British Journal of Cancer|January 11, 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trialE Samalin, O Bouché, S Thézenas, et al.
The British Journal of Radiology|December 6, 2002
Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteriaV Trillet-Lenoir, G Freyer, P Kaemmerlen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2019
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trialO Trédan, Q Wang, D Pissaloux, et al.
ESMO Open|January 30, 2021
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancerP Heudel, S Chabaud, D Perol, et al.
Pageof 2